查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1567324

唾液腺感染疾病的全球市場:各類型，各用途，各國，企業的分析(2024年～2032年)

Global Salivary Gland Infection Market Report Global Forecast by Type (Diagnosis, Treatment), Application (Hospital, Clinic, Household, Other) Country and Company Analysis 2024-2032
出版日期: | 出版商: Renub Research | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

唾液腺感染的市場規模

預計2023年全球唾液腺感染市場規模將達到29.3億美元，到2032年將達到47.2億美元，2024年至2032年複合年增長率為5.44%，預計。預計該市場的成長主要是由於疾病模式的變化、環境的變化以及各種唾液腺感染的流行。由於研發和臨床試驗資金增加而改進的產品開發也是市場擴張的關鍵驅動力。這個市場主要由診斷和治療方案的進步、自我保健意識的提高以及衛生習慣的改善所推動。

世界各地唾液腺感染概況

當唾液腺或唾液管被細菌或病毒感染時，就會發生唾液腺感染。唾液流量減少可能是由於唾液管堵塞或發炎引起的，這也可能導致感染。這種疾病稱為唾液腺炎。唾液腺感染可以影響任何人，包括嬰兒，但老年人和患有長期疾病的人尤其容易受到影響。這種疾病被稱為唾液腺炎，其特徵是一個或多個唾液腺腫脹和發炎。存在急性和慢性兩種形式。唾液腺炎的確切原因尚不清楚。唾液腺結石（唾液腺結石的形成）有時與這種疾病有關。

由於唾液腺炎，一個或多個唾液腺可能會變得腫脹、敏感或發紅。唾液腺包括耳朵附近的腮腺、舌下腺和下頷腺，以及舌頭、嘴唇、臉頰和上顎上的幾個較小的腺體。這些腺體的分泌物可能會被唾液結石或結石阻塞。

有時唾液腺會受到感染，導致發燒和其他症狀。急性和慢性唾液腺炎的共同特徵是唾液流量減少。用餐時疼痛變得明顯，超過 75% 的患者主訴口乾（口乾症）。其他疾病包括結節病、脫水、營養不良、癌症放射治療、皰疹、愛滋病毒、A/II 型流感、I/II 型副流感、唾液結石、唾液管黏液阻塞、腫瘤和乾燥症候群、結節病和口腔不良。

唾液腺感染市場的成長推動因素

感染率上升

對唾液腺感染替代治療的需求通常是由傳染病的流行所驅動的，特別是細菌、真菌和病毒感染。由於不良的牙齒衛生、生活方式的改變以及對抗生素產生抗藥性的細菌的出現，真菌感染、細菌性唾液腺炎和腮腺炎等疾病的盛行率經常上升。此類病例數量的增加表明需要有效的治療和診斷方法。

隨著人們對唾液腺健康重要性的認識不斷增加，醫療保健專業人員越來越關注識別和治療這些感染。由於興趣的增加，患者越來越早地尋求治療，對尖端治療方案的需求也增加。此外，旨在改善患者預後的研究活動的增加和治療技術的進步增強了市場發展潛力。

唾液腺感染市場概述：各地區

儘管存在各種發展推動因素和障礙，全球唾液腺感染市場在所有地區都在整體成長。隨著治療方案變得更加廣為人知和容易獲得，該行業預計將會成長。

唾液腺感染公司新聞

2022 年 8 月，澳洲推出了世界上第一個 DNA 篩檢計劃，以檢查癌症和心臟病的風險。該倡議是由澳洲莫納什大學領導的一項全國性合作計畫。

2022 年 6 月，Goodbody Health Inc. 推出了四項新測試，利用基因分析來估計個人 10 年內罹患心臟病和癌症的風險。這些產品的推出預計將加速該領域的未來成長。

本報告提供全球唾液腺感染疾病市場相關調查，提供市場規模與成長率，成長推動因素與課題，各地區市場佔有率，主要企業的分析等資訊。

目錄

第1章 簡介

第2章 調查和調查手法

第3章 摘要整理

第4章 市場動態

  • 成長促進因素
  • 課題

第5章 全球唾液腺感染疾病市場

第6章 全球唾液腺感染疾病的市場佔有率的分析

  • 各類型
  • 各用途
  • 各國

第7章 類型 - 全球唾液腺感染疾病市場

  • 診斷
  • 治療

第8章 用途 - 全球唾液腺感染疾病市場

  • 醫院
  • 診療所
  • 家庭
  • 其他

第9章 國家- 全球唾液腺感染疾病市場

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 比利時
    • 荷蘭
    • 土耳其
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 泰國
    • 馬來西亞
    • 印尼
    • 紐西蘭
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東·非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章 波特的五力分析

第11章 SWOT分析

第12章 主要企業的分析

  • AbbVie Inc.
  • Allergan plc.
  • AstraZeneca
  • FUJIFILM Holdings Corporation
  • General Electric Company
  • GlaxoSmithKline plc.
  • Merck & Co
  • Pfizer Inc.
  • Siemens Healthcare GmbH
簡介目錄

Salivary Gland Infection Market Size

The Salivary Gland Infection market is expected to reach US$ 2.93 Billion in 2023 to US$ 4.72 Billion by 2032, with a CAGR of 5.44 % from 2024 to 2032. The market is expected to rise due in large part to changing disease patterns, environmental changes, and the rising prevalence of various salivary gland infections. Improved product development as a result of increased financing for R&D and clinical trials is another important driver of market expansion. The market is mostly driven by advances in diagnosis and treatment choices, more self-care awareness, and improved hygiene practices.

Global Salivary Gland Infection Overview

A salivary gland infection happens when the salivary gland or duct is infected by bacteria or viruses. Reduced saliva flow, which may be brought on by an obstruction or inflammation of the salivary duct, may be the cause of the infection. The illness is known as sialadenitis. While salivary gland infections can strike anybody, including infants, the elderly and those with long-term illnesses are particularly vulnerable to the ailment. The illness known as salivalentitis is typified by swelling and inflammation of one or more salivary glands. Both acute and chronic versions exist. Unknown is the precise cause of sialadenitis. Sialolithiasis, or the production of salivary gland stones, may occasionally be linked to the disorder.

One or more salivary glands may swell, become sensitive, or become red as a result of sialadenitis. These include several tiny glands in the tongue, lips, cheeks, and palate in addition to the mouth's parotid, sublingual, and submaxillary glands, which are situated close to the ear. Any of these glands' secretions may be obstructed by salivary stones, or calculi.

Occasionally, the gland may get infected, resulting in fever and other problems. A characteristic shared by both the acute and chronic forms of sialadenitis is decreased salivary flow. During eating, the pain is more noticeable, and over 75% of patients report having dry mouth (xerostomia). Additional medical conditions include sarcoidosis, dehydration, malnutrition, radiation treatment for cancer, herpes, HIV, influenza A and type II, parainfluenza types I and II, salivary stones, mucus-blocking salivary ducts, tumors, Sjogren's syndrome, sarcoidosis, and inadequate oral hygiene, which can reduce salivary production and cause sialadenitis.

Growth Drivers for the Salivary Gland Infection Market

Rising infection rates

The need for treatment alternatives for salivary gland infections is mostly driven by the rising prevalence of infections, especially bacterial, fungal, and viral infections. The prevalence of illnesses such fungal infections, bacterial sialadenitis, and the mumps is rising, frequently as a result of poor dental hygiene, changing lifestyles, and the emergence of germs resistant to antibiotics. The increase in instances emphasizes the necessity of efficient therapeutic and diagnostic approaches.

Healthcare professionals are becoming more alert in identifying and treating these infections as knowledge of the significance of salivary gland health develops. Patients are encouraged to seek medical attention earlier as a result of this increased focus, which increases demand for cutting-edge treatment choices. Furthermore, the market's development potential is reinforced by the increased research activities and advancements in therapeutic technologies aimed at improving patient outcomes.

Improvements in lifestyle

Changes in lifestyle, such as nutrition and stress levels, have a big effect on dental health and raise the risk of salivary gland infections. Poor dental hygiene can result from diets heavy in sugar and processed foods, which in turn encourages bacterial development and raises the risk of illnesses. Furthermore, problems with the salivary glands can be made worse by dehydration and decreased salivation-both of which are prevalent in people who lead unhealthy lives.

Moreover, it is well recognized that high stress levels impair immune function, leaving people more vulnerable to illnesses. Prolonged stress can cause bad habits like teeth grinding, which can harm salivary gland function. The demand for efficient treatment choices is rising in tandem with the growing knowledge of these lifestyle-related dangers, underscoring the necessity of novel therapeutics to address these health issues.

Salivary Gland Infection Market Overview by Regions

With different development drivers and obstacles, the worldwide market for salivary gland infections is generally rising across all geographies. The industry is expected to develop as long as treatment choices become more widely known and accessible. An overview of the market by region is given below:

North America Salivary Gland Infection Market

United States

The increasing prevalence of illnesses like bacterial sialadenitis and viral infections like mumps has led to a thriving market for salivary gland infections in the US. The availability of efficient diagnostic tools and treatment choices is improved by an advanced healthcare infrastructure and a strong focus on research and innovation. The management of chronic diseases and improved oral health are two areas where early detection and action are aided. Furthermore, an elderly population is more prone to illnesses, which increases demand in the market. Overall, the market for salivary gland infections is expected to rise in the United States due to continual improvements in healthcare.

Europe Salivary Gland Infection Market

Germany

Germany's market for salivary gland infections is steadily expanding due to an older population and rising oral health awareness. There is an increasing need for efficient diagnosis and treatment alternatives due to the rising occurrence of diseases like mumps and sialadenitis. Market expansion is further supported by a concentration on research and development and an advanced healthcare infrastructure. Oral hygiene-related public health efforts improve patient outcomes by facilitating early diagnosis and intervention. Germany is positioned to be a major participant in the European salivary gland infection market as healthcare costs rise.

Asia Pacific Salivary Gland Infection Market

China

China's market for salivary gland infections is expanding significantly due to factors such changing eating patterns, growing urbanization, and growing awareness of oral health. Changes in lifestyle and environmental factors are contributing to an increase in the occurrence of illnesses like sialadenitis. Early infection diagnosis and management are being made easier by advancements in healthcare infrastructure and access to cutting-edge diagnostic and treatment alternatives. Market expansion is further supported by government measures focused at improving public health education. China is emerging as a major participant in the worldwide market for salivary gland infections as the healthcare industry continues to change.

Middle East & Africa Salivary Gland Infection Market

Saudi Arabia

Saudi Arabia's market for salivary gland infections is expanding as a result of improving oral health awareness and the prevalence of illnesses like sialadenitis. Dietary modifications and lifestyle choices are among the factors that increase the likelihood of developing these illnesses. The government's emphasis on enhancing access to specialized services and the infrastructure supporting healthcare improves diagnosis and treatment options. Furthermore, oral hygiene education programs run by public health organizations are essential for early detection and prevention. Saudi Arabia is establishing itself as an emerging market in the field of salivary gland infections as medical technology advances.

Salivary Gland Infection Company Analysis

The major participants in the Salivary Gland Infection market includes AbbVie Inc., Allergan plc., AstraZeneca, FUJIFILM Holdings Corporation, General Electric Company, GlaxoSmithKline plc., Merck & Co, Pfizer Inc., Siemens Healthcare GmbH.

Salivary Gland Infection Company News

In August 2022, t One of the world's first DNA screening programs for cancer and heart disease risk was introduced in Australia with free salivary DNA tests. The initiative is a national collaboration headed by Monash University in Australia.

In June 2022, Goodbody Health Inc. has introduced four new tests that use genetic analysis to estimate an individual's 10-year risk of developing heart disease or cancer. It is anticipated that these launches would accelerate this segment's future growth.

Types- Industry is divided into 2 viewpoints:

1. Diagnosis

2. Treatment

Application- Industry is divided into 4 viewpoints:

1. Hospital

2. Clinic

3. Household

4. Other

Countries- Industry is divided into 25 viewpoints:

North America

  • United States
  • Canada

Europe

  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • Belgium
  • Netherlands
  • Turkey

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Thailand
  • Malaysia
  • Indonesia
  • New Zealand

Latin America

  • Brazil
  • Mexico
  • Argentina

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • United Arab Emirates

All companies have been covered with 5 Viewpoints

1. Overviews

2. Key Person

3. Recent Developments & Strategies

4. Product Portfolio & Product Launch in Last 1 Year

5. Revenue

Company Analysis

1. AbbVie Inc.

2. Allergan plc.

3. AstraZeneca

4. FUJIFILM Holdings Corporation

5. General Electric Company

6. GlaxoSmithKline plc.

7. Merck & Co

8. Pfizer Inc.

9. Siemens Healthcare GmbH

Key Questions Answered in Report:

1. How big is the Salivary Gland Infection industry?

2. What is the Salivary Gland Infection growth rate?

3. Who are the key players in Salivary Gland Infection industry?

4. What are the factors driving the Salivary Gland Infection industry?

5. Which Region held the largest market share in the Salivary Gland Infection industry?

6. What segments are covered in the Salivary Gland Infection Market report?

Table of Contents

1. Introductions

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Driver
  • 4.2 Challenges

5. Global Salivary Gland Infection Market

6. Global Salivary Gland Infection Market Share Analysis

  • 6.1 By Types
  • 6.2 By Application
  • 6.3 By Country

7. Types - Global Salivary Gland Infection Market

  • 7.1 Diagnosis
  • 7.2 Treatment

8. Application - Global Salivary Gland Infection Market

  • 8.1 Hospital
  • 8.2 Clinic
  • 8.3 Household
  • 8.4 Other

9. Country - Global Industrial Hemp Market

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
  • 9.2 Europe
    • 9.2.1 France
    • 9.2.2 Germany
    • 9.2.3 Italy
    • 9.2.4 Spain
    • 9.2.5 United Kingdom
    • 9.2.6 Belgium
    • 9.2.7 Netherlands
    • 9.2.8 Turkey
  • 9.3 Asia Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 Australia
    • 9.3.5 South Korea
    • 9.3.6 Thailand
    • 9.3.7 Malaysia
    • 9.3.8 Indonesia
    • 9.3.9 New Zealand
  • 9.4 Latin America
    • 9.4.1 Brazil
    • 9.4.2 Mexico
    • 9.4.3 Argentina
  • 9.5 Middle East & Africa
    • 9.5.1 South Africa
    • 9.5.2 Saudi Arabia
    • 9.5.3 United Arab Emirates

10. Porter's Five Forces

  • 10.1 Bargaining Power of Buyers
  • 10.2 Bargaining Power of Suppliers
  • 10.3 Degree of Rivalry
  • 10.4 Threat of New Entrants
  • 10.5 Threat of Substitutes

11. SWOT Analysis

  • 11.1 Strength
  • 11.2 Weakness
  • 11.3 Opportunity
  • 11.4 Threat

12. Key Players Analysis

  • 12.1 AbbVie Inc.
    • 12.1.1 Overviews
    • 12.1.2 Key Person
    • 12.1.3 Recent Developments & Strategies
    • 12.1.4 Product Portfolio & Product Launch in Last 1 Year
    • 12.1.5 Revenue
  • 12.2 Allergan plc.
    • 12.2.1 Overviews
    • 12.2.2 Key Person
    • 12.2.3 Recent Developments & Strategies
    • 12.2.4 Product Portfolio & Product Launch in Last 1 Year
    • 12.2.5 Revenue
  • 12.3 AstraZeneca
    • 12.3.1 Overviews
    • 12.3.2 Key Person
    • 12.3.3 Recent Developments & Strategies
    • 12.3.4 Product Portfolio & Product Launch in Last 1 Year
    • 12.3.5 Revenue
  • 12.4 FUJIFILM Holdings Corporation
    • 12.4.1 Overviews
    • 12.4.2 Key Person
    • 12.4.3 Recent Developments & Strategies
    • 12.4.4 Product Portfolio & Product Launch in Last 1 Year
    • 12.4.5 Revenue
  • 12.5 General Electric Company
    • 12.5.1 Overviews
    • 12.5.2 Key Person
    • 12.5.3 Recent Developments & Strategies
    • 12.5.4 Product Portfolio & Product Launch in Last 1 Year
    • 12.5.5 Revenue
  • 12.6 GlaxoSmithKline plc.
    • 12.6.1 Overviews
    • 12.6.2 Key Person
    • 12.6.3 Recent Developments & Strategies
    • 12.6.4 Product Portfolio & Product Launch in Last 1 Year
    • 12.6.5 Revenue
  • 12.7 Merck & Co
    • 12.7.1 Overviews
    • 12.7.2 Key Person
    • 12.7.3 Recent Developments & Strategies
    • 12.7.4 Product Portfolio & Product Launch in Last 1 Year
    • 12.7.5 Revenue
  • 12.8 Pfizer Inc.
    • 12.8.1 Overviews
    • 12.8.2 Key Person
    • 12.8.3 Recent Developments & Strategies
    • 12.8.4 Product Portfolio & Product Launch in Last 1 Year
    • 12.8.5 Revenue
  • 12.9 Siemens Healthcare GmbH
    • 12.9.1 Overviews
    • 12.9.2 Key Person
    • 12.9.3 Recent Developments & Strategies
    • 12.9.4 Product Portfolio & Product Launch in Last 1 Year
    • 12.9.5 Revenue